Glucotrack, Inc.

Glucotrack develops an implantable continuous blood glucose monitor (CBGM) for patients with Type 1 diabetes or Type 2 diabetes requiring insulin therapy. The device uses an intravascular approach—a subcutaneous implant with a lead inserted directly into a blood vessel—to measure blood glucose continuously with minimal measurement lag, distinguishing it from existing external continuous glucose monitors that measure interstitial fluid. Glucotrack serves the large and growing global diabetes market, which encompasses hundreds of millions of patients, and generates revenue through the sale of implantable devices and related services; the company expects these devices to require less frequent replacement than competing external monitors and aims to obtain regulatory approval and reimbursement from major payors.